NCT05813483

Brief Summary

A Prospective, Single-center, Single-blind, Randomized split-face, controlled trial will be conducted. The goal of this clinical trial is to evaluate the efficacy and satisfaction of the Skinceuticals skin care product (CE) for skin repair following fraxel laser treatment and explore the medical value of fraxel laser therapy combined with Skinceuticals skin care product

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2023

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 3, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 14, 2023

Completed
3 days until next milestone

Study Start

First participant enrolled

April 17, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

April 14, 2023

Status Verified

April 1, 2023

Enrollment Period

6 months

First QC Date

April 3, 2023

Last Update Submit

April 3, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in erythema score

    Scoring criteria: 0 (no erythema), 1 (mild erythema), 2 (moderate erythema), and 3 (severe erythema)

    at day 7 post-procedure

Secondary Outcomes (8)

  • Change from baseline in erythema score

    days 1, 3, 5 post-procedure

  • Change from baseline in edema score

    days 1, 3, 5 ,7 post-procedure

  • Change from baseline in Erythema Index (EI)

    days 1, 3, 5 ,7 post-procedure

  • Change from baseline in melanin index(MI) Change from baseline in melanin index(MI)

    days 1, 3, 5 ,7 post-procedure

  • Change from baseline in stratum corneum water content

    days 1, 3, 5 ,7 post-procedure

  • +3 more secondary outcomes

Study Arms (2)

Test group

EXPERIMENTAL

fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection

Other: Skinceuticals skin care product(CE)Other: fraxel laser therapy

Control group

OTHER

fraxel laser therapy combined with routine moisturizing and sun protection

Other: fraxel laser therapy

Interventions

fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection

Test group

fraxel laser therapy combined with routine moisturizing and sun protection

Control groupTest group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Chinese subjects aged 18-65 years (inclusive);
  • Subjects with Fitzpatrick skin type II-IV;
  • Subjects with consistent facial skin status on both sides and planned to receive fraxel laser treatment;
  • Subjects are willing to follow the requirements of the study protocol and complete the corresponding procedures;
  • Subjects understand the nature of the study and sign the informed consent form (ICF).

You may not qualify if:

  • Subjects with photosensitive skin or photosensitization-related diseases;
  • Subjects with a history of skin pigmentation, such as pigmentation caused by sex hormone factors (pregnancy, oral contraceptives);
  • Subjects with hypertrophic scar or scar constitution;
  • Subjects with autoimmune diseases, endocrine diseases or liver diseases that may lead to skin color changes;
  • Subjects who have received steroid/phototoxic drugs or laser treatment on the face within 3 months before enrollment;
  • Subjects with a history of sun exposure within 2 weeks prior to enrollment;
  • Subjects who are known to be contraindicated to fraxel laser therapy or CE (or allergic to other skin care components);
  • Subjects with known infection and inflammation in the intended treatment site;
  • Female subjects who are pregnant, lactating or plan to become pregnant;
  • Subjects who plan to use other drugs affecting skin color or intend to undergo other laser therapy and sunbathing during the treatment;
  • Subjects who are participating in other drug or medical device clinical trials;
  • Other subjects who are not suitable for this study as assessed by the investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 3, 2023

First Posted

April 14, 2023

Study Start

April 17, 2023

Primary Completion

September 30, 2023

Study Completion

December 31, 2023

Last Updated

April 14, 2023

Record last verified: 2023-04